Abstract
Abstract Introduction: This study is aimed to compare the predictive efficacy of BRCAPRO and MYRIAD BRCA risk calculator in patients tested in Korean ethnicity. Methods: Individuals, who received gene test on BRCA mutation from November 2010 to August 2016, were recruited from database of department of obstetrics and gynecology at a single institute in Korea. Observed BRCA1 and BRCA2 mutation status was compared with predicted carrier probabilities under the BRCAPRO, and MYRIAD BRCA risk calculator. Risk assessment for all patients was calculated using the CancerGene assessment software. Results: Total of 279 patients was recruited, and 99.3% (277 out of 279) had Korean ethnicity. The mean age at presentation was 52 years. Out of the 279 individuals, 206 had ovarian cancer, 36 had breast cancer, 26 had double primary ovarian/breast cancer, and 11 had no cancer. Fifty five individuals had family history of ovarian/breast cancer in first degree relatives. Sixty three patients (22.6%) tested positive for a BRCA mutation (45 BRCA1, 18 BRCA2). The mean BRCAPRO and MYRIAD score for all patients was 6.4% and 7.7%, respectively. The BRCAPRO and MYRIAD scores were significantly higher for patients who tested positive for a BRCA mutation (30.4% vs. 6.3%, P < 0.001, 12.1% vs. 7.7%, P < 0.001, respectively). The area under the receiver operating characteristics curves were 0.762, and 0.751 for all patients for the BRCAPRO and MYRIAD score to predict the risk of carrying a BRCA mutation. Conclusion: BRCAPRO and MYRIAD appear to be valid risk assessment tools for determining the risk of carrying a BRCA mutation in Korean ethnicity. Citation Format: Kyung Jin Eoh, Hyung Seok Park, Ji Soo Park, Seung-Tae Lee, Jeongwoo Han, Jung-Yun Lee, Sunghoon Kim, Sang Wun Kim, Young Tae Kim, Eun Ji Nam. BRCA1 and BRCA 2 mutation predictions using BRACAPRO and MYRIAD models in patients with Korean ethnicity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4283. doi:10.1158/1538-7445.AM2017-4283
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
